Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotersen in TTR Amyloid Cardiomyopathy
NCT03702829Phase 2Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Feb 2019
- Primary completion
- Dec 2021
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of inotersen in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Brigham and Women's Hospital. Started Feb 2019; status: terminated.
02
Drugs
inotersen
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT03702829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702829.